Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40 weeks post menstrual age: a retrospective case series study
Abstract Background Type 1 retinopathy of prematurity (ROP) is occasionally observed in preterm infants after the postmenstrual age (PMA) of 40 weeks; however, evidence-based treatment guidelines are largely lacking. In this study, we report the clinical characteristics of preterm infants with type...
Main Authors: | Jiao Lyu, Qi Zhang, Chunli Chen, Yu Xu, Xunda Ji, Peiquan Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-02-01
|
Series: | BMC Ophthalmology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12886-019-1067-4 |
Similar Items
-
Clinical effect of semi-panretinal laser photocoagulation in prethreshold and threshold retinopathy of premature infants
by: He Cao, et al.
Published: (2019-08-01) -
Factors Associated with Retinopathy of Prematurity in Hospitalized Preterm Infants in Sanandaj, Iran
by: Majid Mansouri, et al.
Published: (2016-09-01) -
Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity
by: Anil Babanrao Gangwe, et al.
Published: (2021-01-01) -
Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity
by: Patel SN, et al.
Published: (2019-08-01) -
Retinopathy of Prematurity and Blood Transfusion Protocols
by: P Mohagheghi, et al.
Published: (2003-10-01)